Overall, TACT showed that infusions of disodium EDTA chelation therapy produced a modest reduction in cardiovascular events. However, further examination of the data showed that chelation therapy benefitted only the patients with diabetes.
Patients with diabetes, who made up approximately one-third of the 1,708 TACT participants, had a 41 percent overall reduction in the risk of any cardiovascular event; a 40 percent reduction in the risk of death from heart disease, nonfatal stroke, or nonfatal heart attack; a 52 percent reduction in recurrent heart attacks; and a 43 percent reduction in death from any cause. In contrast, there was no significant benefit of EDTA treatment in participants who didn't have diabetes.
The TACT study team also looked at the impact of taking high-dose vitamins and minerals in addition to chelation therapy. They found that chelation plus high-dose vitamins and minerals produced the greatest reduction in risk of cardiovascular events versus placebo.